Colorectal Cancer (CRC) Recruiting Phase 2 Trials for Fruquintinib (DB11679)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06484153	Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma	Treatment	Fruquintinib (DB11679) Pembrolizumab (DB09037) Pirfenidone (DB04951)
NCT06148402	Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer	Treatment	Camrelizumab (DB14776) Capecitabine (DB01101) Fruquintinib (DB11679)
NCT07235293	A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.	Treatment	Atezolizumab (DB11595) DSP107 (DB17501) Fruquintinib (DB11679)
NCT07011576	A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)	Treatment	Fluorouracil (DB00544) Fruquintinib (DB11679) Irinotecan (DB00762) Leucovorin (DB00650)
NCT06992258	A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer	Treatment	Fruquintinib (DB11679) Tipiracil (DB09343) Trifluridine (DB00432)
NCT06441565	Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer	Treatment	Fluorouracil (DB00544) Fruquintinib (DB11679) Oxaliplatin (DB00526)
NCT06356584	Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases	Treatment	Fruquintinib (DB11679) Sintilimab (DB15765)
NCT06168786	Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC	Treatment	Cadonilimab (DB16680) Fruquintinib (DB11679)
NCT05771181	Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients	Treatment	Fruquintinib (DB11679) Tislelizumab (DB14922) Vitamin E (DB00163)
NCT05571644	Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer	Treatment	Cadonilimab (DB16680) Fluorouracil (DB00544) Fruquintinib (DB11679) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07003022	Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC	Treatment	Bevacizumab (DB00112) Cadonilimab (DB16680) Fruquintinib (DB11679) Regorafenib (DB08896)
NCT05954429	A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study	Treatment	Fruquintinib (DB11679) Serplulimab (DB17451)